Ex vivo tumor testing platform for predicting clinical response to platinum-based therapy in patients with high grade serous ovarian cancer

被引：0
|
作者：
Ottevanger, P. B.
Kroep, Judith R.
van Persijn-van Meerten, Els L.
van Altena, Anne M.
de Kroon, Cornelis
Ceton, Lieke J.
Montero, Marta G.
van der Meer, Donny J.
Vader, Willemijn
机构：
[1] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands
[2] Leiden Univ, Med Ctr, Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Radiol, Leiden, Netherlands
[4] VitroScan BV, Leiden, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5563
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Testing the Metal of ERCC2 in Predicting the Response to Platinum-Based Therapy
    Turchi, John J.
    Woods, Derek S.
    Vander Vere-Carozza, Pamela
    CANCER DISCOVERY, 2014, 4 (10) : 1118 - 1119
  • [22] Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy
    Hans Bösmüller
    Sophie Haitchi-Petnehazy
    Gerald Webersinke
    Renate Marschon
    Franz Roithmeier
    Wolfgang Stummvoll
    Tanja Fehm
    Margit Klier-Richter
    Irina Bonzheim
    Annette Staebler
    Falko Fend
    Virchows Archiv, 2011, 459
  • [23] Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy
    Boesmueller, Hans
    Haitchi-Petnehazy, Sophie
    Webersinke, Gerald
    Marschon, Renate
    Roithmeier, Franz
    Stummvoll, Wolfgang
    Fehm, Tanja
    Klier-Richter, Margit
    Bonzheim, Irina
    Staebler, Annette
    Fend, Falko
    VIRCHOWS ARCHIV, 2011, 459 (02) : 183 - 191
  • [24] In vivo tumor growth of high-grade serous ovarian cancer cell lines
    Mitra, Anirban K.
    Davis, David A.
    Tomar, Sunil
    Roy, Lynn
    Gurler, Hilal
    Xie, Jia
    Lantvit, Daniel D.
    Cardenas, Horacio
    Fang, Fang
    Liu, Yueying
    Loughran, Elizabeth
    Yang, Jing
    Stack, M. Sharon
    Emerson, Robert E.
    Dahl, Karen D. Cowden
    Barbolina, Maria V.
    Nephew, Kenneth P.
    Matei, Daniela
    Burdette, Joanna E.
    GYNECOLOGIC ONCOLOGY, 2015, 138 (02) : 372 - 377
  • [25] Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer
    Alkema, N. G.
    Tomar, T.
    van der Zee, A. G. J.
    Everts, M.
    Meersma, G. J.
    Hollema, H.
    de Jong, S.
    van Vugt, M. A. T. M.
    Wisman, G. B. A.
    GYNECOLOGIC ONCOLOGY, 2014, 133 (03) : 591 - 598
  • [26] Tumour-associated inflammatory cytokines are reduced following primary platinum-based chemotherapy in plasma of high-grade serous ovarian cancer patients
    Boehm, S.
    Ennis, D.
    Dowe, T.
    Canosa, M.
    McNeish, I.
    Lockley, M.
    Balkwill, F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S736 - S736
  • [27] Characterisation of Proteomic heterogeneity following platinum therapy in High-grade Serous Ovarian Cancer
    Wulandari, Ratri
    Nixon, Katherine
    Rama, Nona
    Curry, Ed
    Cunnea, Paula
    Fotopoulou, Christina
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2022, 129 : 40 - 41
  • [28] High-grade serous Ovarian Cancer: TP53 Mutations and Platinum Response
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (07)
  • [29] RFWD3: A Potential Biomarker for Platinum Response in High Grade Serous Ovarian Cancer
    Taylor, S.
    Hollis, R. L.
    Gourley, C.
    Herrington, C. S.
    Arends, M. J.
    Langdon, S. P.
    JOURNAL OF PATHOLOGY, 2022, 256 : S12 - S12
  • [30] Patient derived organoids as ex-vivo models for high grade serous ovarian cancer research
    Clark, James
    Fotopoulou, Christina
    Ploski, Jennifer
    Dickie, Catriona
    Kondyliou, Lydia
    Krell, Jonathan
    Cunnea, Paula
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A177 - A177
12345